Skip to main content
Erschienen in: Journal of Neural Transmission 5/2020

08.05.2020 | Neurology and Preclinical Neurological Studies - Original Article

Creation of a gene expression classifier for predicting Parkinson’s disease rate of progression

verfasst von: Jose Martin Rabey, Jennifer Yarden, Nir Dotan, Danit Mechlovich, Peter Riederer, Moussa B. H. Youdim

Erschienen in: Journal of Neural Transmission | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Parkinson’s disease (PD) etiology is heterogeneous, genetic, and multi-factorial, resulting in a varied disease from a mild slow progression to a more severe rapid progression. Prognostic information on the nature of the patient’s disease at diagnosis aids the physician in counseling patients on treatment options and life planning. In a cohort of PD patients from the PPMI study, the relative gene expression levels of SKP1A, UBE2K, ALDH1A1, PSMC4, HSPA8 and LAMB2 were measured in baseline blood samples by real-time quantitative PCR. At baseline PD patients were up to 2 years from diagnosis, H&Y scale ≤ 2 and PD treatment naïve. PD-Prediction algorithm comprised of ALDH1A1, LAMB2, UBE2K, SKP1A and age was created by logistic regression for predicting progression to ≤ 70% Modified Schwab and England Activities of Daily Living (S&E-ADL). In relation to patients negative for PD-Prediction (n = 180), patients positive (n = 30) for Cutoff-1 (at 82% specificity, 80.0% sensitivity) had positive hazard ratio (HR+) of 10.6 (95% CI, 2.2–50.1), and positive (n = 23) for Cutoff-2 (at 93% specificity, 47% sensitivity) had HR+ of 17.1 (95% CI, 3.2–89.9) to progress to ≤ 70% S&E-ADL within 3 years (P value < 0.0001). Likewise, patients positive for PD-Prediction Cutoff-1 (n = 49) had HR+ 4.3 (95% CI, 1.6–11.6) for faster time to H&Y 3 in relation to patients negative (n = 170) for PD-Prediction (P value = 0.0002). Our findings show an algorithm that seems to predict fast PD progression and may potentially be used as a tool to assist the physician in choosing an optimal treatment plan, improving the patient’s quality of life and overall health outcome.
Literatur
Zurück zum Zitat Ahlskog E (2000) Approach to the patient with a movement disorder: basic principles of neurologic diagnosis. From Parkinson’s disease and movement disorders : diagnosis and treatment guidelines for the practicing physician (edited by Adler CH and Ahlskog JE). Humana Press, Totowa, New Jersey, pp 3–34 Ahlskog E (2000) Approach to the patient with a movement disorder: basic principles of neurologic diagnosis. From Parkinson’s disease and movement disorders : diagnosis and treatment guidelines for the practicing physician (edited by Adler CH and Ahlskog JE). Humana Press, Totowa, New Jersey, pp 3–34
Zurück zum Zitat Anderson DW, Schray RC, Duester G, Schneider JS (2011) Functional significance of aldehyde dehydrogenase ALDH1A1 to the nigrostriatal dopamine system. Brain Res 1408:81–87CrossRef Anderson DW, Schray RC, Duester G, Schneider JS (2011) Functional significance of aldehyde dehydrogenase ALDH1A1 to the nigrostriatal dopamine system. Brain Res 1408:81–87CrossRef
Zurück zum Zitat Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Teb S, Foltynie T (2017) Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390:1664–1675CrossRef Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Teb S, Foltynie T (2017) Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390:1664–1675CrossRef
Zurück zum Zitat Becerra JE, Zorro O, Ruiz-Gaviria R, Castañeda-Cardona C, Otálora-Esteban M, Henao S, Navarrete S, Acevedo JC, Rosselli D (2016) Economic analysis of deep brain stimulation in Parkinson disease: systematic review of the literature. World Neurosurg 93:44–49CrossRef Becerra JE, Zorro O, Ruiz-Gaviria R, Castañeda-Cardona C, Otálora-Esteban M, Henao S, Navarrete S, Acevedo JC, Rosselli D (2016) Economic analysis of deep brain stimulation in Parkinson disease: systematic review of the literature. World Neurosurg 93:44–49CrossRef
Zurück zum Zitat Birkmayer W, Riederer P, Youdim MBH (1979) Distinction between benign and malignant type of Parkinson’s disease. Clin Neurol Neurosurg 81:158–164CrossRef Birkmayer W, Riederer P, Youdim MBH (1979) Distinction between benign and malignant type of Parkinson’s disease. Clin Neurol Neurosurg 81:158–164CrossRef
Zurück zum Zitat Braak H, Rub U, Gai WP, Del Tredici K (2003) Idiopathic Parkinson’s disease: possible routes by which vulnerable neurons types may be subject to neuroinvasion by an unknown pathogen. J Neural Trans 110:510–537CrossRef Braak H, Rub U, Gai WP, Del Tredici K (2003) Idiopathic Parkinson’s disease: possible routes by which vulnerable neurons types may be subject to neuroinvasion by an unknown pathogen. J Neural Trans 110:510–537CrossRef
Zurück zum Zitat Dorsey TS, Voss DR, Shprecher LM, Deuel CA, Beck IF, Gardiner MA, Coles RS, Burns FJ, Marshall KMB (2010) A U.S. survey of patients with Parkinson’s disease: satisfaction with medical care and support groups. Mov Disord 25:2128–2135CrossRef Dorsey TS, Voss DR, Shprecher LM, Deuel CA, Beck IF, Gardiner MA, Coles RS, Burns FJ, Marshall KMB (2010) A U.S. survey of patients with Parkinson’s disease: satisfaction with medical care and support groups. Mov Disord 25:2128–2135CrossRef
Zurück zum Zitat Fahn S, Jankovic J, Hallet M (2011) Principles and practice of movement disorders. Elsevier Publication, Amsterdam Fahn S, Jankovic J, Hallet M (2011) Principles and practice of movement disorders. Elsevier Publication, Amsterdam
Zurück zum Zitat Filatova EV, Shadrina MI, Alieva AKh, Kolacheva AA, Slominsky PA, Ugrumov MV (2014) Expression analysis of genes of ubiquitin-proteasome protein degradation system in MPTP-induced mice models of early stages of Parkinson’s disease. Dokl Biochem Biophys 456:116–118CrossRef Filatova EV, Shadrina MI, Alieva AKh, Kolacheva AA, Slominsky PA, Ugrumov MV (2014) Expression analysis of genes of ubiquitin-proteasome protein degradation system in MPTP-induced mice models of early stages of Parkinson’s disease. Dokl Biochem Biophys 456:116–118CrossRef
Zurück zum Zitat Fishman-Jakob T, Reznichenko L, Youdim MBH, Mandel SA (2009) A sporadic Parkinson disease model via silencing of the ubiquitine-proteasome/E3 ligase component SKP1A. J Biol Chem 284:32835–32932CrossRef Fishman-Jakob T, Reznichenko L, Youdim MBH, Mandel SA (2009) A sporadic Parkinson disease model via silencing of the ubiquitine-proteasome/E3 ligase component SKP1A. J Biol Chem 284:32835–32932CrossRef
Zurück zum Zitat Fullard ME, Tran B, Xie S, Toledo JB, Scordia C, Linder C, Purri R, Weintraub D, Duda JE, Chahine LM, Morley JF (2016) Olfactory impairment predicts cognitive decline in early Parkinson’s disease. Parkinsonism Relat Disord 25:45–51CrossRef Fullard ME, Tran B, Xie S, Toledo JB, Scordia C, Linder C, Purri R, Weintraub D, Duda JE, Chahine LM, Morley JF (2016) Olfactory impairment predicts cognitive decline in early Parkinson’s disease. Parkinsonism Relat Disord 25:45–51CrossRef
Zurück zum Zitat George S, Brundin P (2015) Immunotherapy in Parkinson’s disease: micromanaging alpha-synuclein aggregation. J Parkinsons Dis 5:213–222 George S, Brundin P (2015) Immunotherapy in Parkinson’s disease: micromanaging alpha-synuclein aggregation. J Parkinsons Dis 5:213–222
Zurück zum Zitat Grünblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, Li J, Ravid R, Roggendorf W, Riederer P, Youdim MB (2004) Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 111:1543–1573CrossRef Grünblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, Li J, Ravid R, Roggendorf W, Riederer P, Youdim MB (2004) Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 111:1543–1573CrossRef
Zurück zum Zitat Grünblatt E, Zehetmayer S, Jacob CP, Müller T, Jost WH, Riederer P (2010) Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson’s disease. J Neural Transm 117:1387–1393CrossRef Grünblatt E, Zehetmayer S, Jacob CP, Müller T, Jost WH, Riederer P (2010) Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson’s disease. J Neural Transm 117:1387–1393CrossRef
Zurück zum Zitat Hirsch E, Jenners P, Przedborski S (2013) Pathogenesis of Parkinson’s disease. Mov Dis 28(1):24–30CrossRef Hirsch E, Jenners P, Przedborski S (2013) Pathogenesis of Parkinson’s disease. Mov Dis 28(1):24–30CrossRef
Zurück zum Zitat Hoehn M, Yahr M (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442CrossRef Hoehn M, Yahr M (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442CrossRef
Zurück zum Zitat Lang AE, Espay AJ (2018) Disease modification in Parkinson’s disease: current approaches, challenges, and future considerations. Mov Disord 33(2018):660–677CrossRef Lang AE, Espay AJ (2018) Disease modification in Parkinson’s disease: current approaches, challenges, and future considerations. Mov Disord 33(2018):660–677CrossRef
Zurück zum Zitat Lawton M, Baig F, Rolinski M, Ruffman C, Nithi K, Hu MT (2015) Parkinson’s disease subtypes in the Oxford Parkinson disease centre (OPDC) discovery cohort. J Parkinsons Dis 5:269–279CrossRef Lawton M, Baig F, Rolinski M, Ruffman C, Nithi K, Hu MT (2015) Parkinson’s disease subtypes in the Oxford Parkinson disease centre (OPDC) discovery cohort. J Parkinsons Dis 5:269–279CrossRef
Zurück zum Zitat Li S, Le W (2017) Biomarker discovery in Parkinson’s disease: present challenges and future opportunities. Neurosci Bull 33(5):481–482CrossRef Li S, Le W (2017) Biomarker discovery in Parkinson’s disease: present challenges and future opportunities. Neurosci Bull 33(5):481–482CrossRef
Zurück zum Zitat Matsumoto JY (2000) Tremor disorders overview. Chapter 21. From Adler CH, Ashlskog JE Editors (2000). From Parkinson’s disease and movement disorders. Diagnosis and treatment guidelines for the practicing physician (edited by Adler CH and Ashlkog JE). Humana press, Totowa, New Jersey Matsumoto JY (2000) Tremor disorders overview. Chapter 21. From Adler CH, Ashlskog JE Editors (2000). From Parkinson’s disease and movement disorders. Diagnosis and treatment guidelines for the practicing physician (edited by Adler CH and Ashlkog JE). Humana press, Totowa, New Jersey
Zurück zum Zitat Molochnikov L, Rabey JM, Dobronevsky E, Bonucelli U, Ceravolo R, Frosini D, Grünblatt E, Riederer P, Jacob C, Aharon-Peretz J, Bashenko Y, Youdim MB, Mandel SA (2012) A molecular signature in blood identifies early Parkinson’s disease. Mol Neurodegener 31:7–26 Molochnikov L, Rabey JM, Dobronevsky E, Bonucelli U, Ceravolo R, Frosini D, Grünblatt E, Riederer P, Jacob C, Aharon-Peretz J, Bashenko Y, Youdim MB, Mandel SA (2012) A molecular signature in blood identifies early Parkinson’s disease. Mol Neurodegener 31:7–26
Zurück zum Zitat Nazeri A, Roostaei T, Sadaghiani S, Chakravarty MM, Eberly S, Lang AE, Voineskos AN (2015) Genome-wide variant by serum urate interaction in Parkinson’s disease. Ann Neurol 78:731–741CrossRef Nazeri A, Roostaei T, Sadaghiani S, Chakravarty MM, Eberly S, Lang AE, Voineskos AN (2015) Genome-wide variant by serum urate interaction in Parkinson’s disease. Ann Neurol 78:731–741CrossRef
Zurück zum Zitat Pinho R, Guedes LC, Soreq L, Lobo PP, Mestre T, Coelho M, Rosa MM, Gonçalves N, Wales P, Mendes T, Gerhardt E, Fahlbusch C, Bonifati V, Bonin M, Miltenberger-Miltényi G, Borovecki F, Soreq H, Ferreira JJ, Outeiro F (2016) Gene expression differences in peripheral blood of Parkinson’s disease patients with distinct progression profiles. PLoS ONE 11(6):e0157852CrossRef Pinho R, Guedes LC, Soreq L, Lobo PP, Mestre T, Coelho M, Rosa MM, Gonçalves N, Wales P, Mendes T, Gerhardt E, Fahlbusch C, Bonifati V, Bonin M, Miltenberger-Miltényi G, Borovecki F, Soreq H, Ferreira JJ, Outeiro F (2016) Gene expression differences in peripheral blood of Parkinson’s disease patients with distinct progression profiles. PLoS ONE 11(6):e0157852CrossRef
Zurück zum Zitat Rossi A, Berger K, Chen H et al (2018) Projection of the alence of PD in the coming decades. Revis Mov Disord 33(1):156–161CrossRef Rossi A, Berger K, Chen H et al (2018) Projection of the alence of PD in the coming decades. Revis Mov Disord 33(1):156–161CrossRef
Zurück zum Zitat Schwab RS, England AC (1969) Projection technique for evaluating surgery in Parkinson’s disease. In: Gillingham FJ, Donaldson MC (eds) Third symposium on Parkinson’s disease. Livingston, Edinburgh, pp 152–157 Schwab RS, England AC (1969) Projection technique for evaluating surgery in Parkinson’s disease. In: Gillingham FJ, Donaldson MC (eds) Third symposium on Parkinson’s disease. Livingston, Edinburgh, pp 152–157
Zurück zum Zitat Sever M, Turkyilmaz M, Sevinc C, Cakir A, Ocalan B, Cansev M, Guler MO, Tekinay AB (2016) Regenerative effects of peptide nanofibers in an experimental model of Parkinson’s disease. Acta Biomater 46:79–90CrossRef Sever M, Turkyilmaz M, Sevinc C, Cakir A, Ocalan B, Cansev M, Guler MO, Tekinay AB (2016) Regenerative effects of peptide nanofibers in an experimental model of Parkinson’s disease. Acta Biomater 46:79–90CrossRef
Zurück zum Zitat Singleton AB, Farrer MJ, Bonifati V (2013) The genetics of Parkinson’s disease: progress and therapeutic implications. Mov Disord 28:14–23CrossRef Singleton AB, Farrer MJ, Bonifati V (2013) The genetics of Parkinson’s disease: progress and therapeutic implications. Mov Disord 28:14–23CrossRef
Zurück zum Zitat Singleton AB, Hardy JA, Gasser T (2017) The birth of the modern era of Parkinson’s disease genetics. J Parkinsons Dis 7(Suppl 1):58–59 Singleton AB, Hardy JA, Gasser T (2017) The birth of the modern era of Parkinson’s disease genetics. J Parkinsons Dis 7(Suppl 1):58–59
Zurück zum Zitat Swanson CR, Berlyand Y, Xie SX, Alcalay RN, Chahine LM, Chen-Plotkin AS (2015) Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson’s disease patients. Mov Disord 30:1648–1656CrossRef Swanson CR, Berlyand Y, Xie SX, Alcalay RN, Chahine LM, Chen-Plotkin AS (2015) Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson’s disease patients. Mov Disord 30:1648–1656CrossRef
Zurück zum Zitat Terrelonge M, Marder KS, Weintraub D, Alcalay RN (2016) CSF β-amyloid 1–42 predicts progression to cognitive impairment in newly diagnosed Parkinson disease. J Mol Neurosci 58:88–92CrossRef Terrelonge M, Marder KS, Weintraub D, Alcalay RN (2016) CSF β-amyloid 1–42 predicts progression to cognitive impairment in newly diagnosed Parkinson disease. J Mol Neurosci 58:88–92CrossRef
Zurück zum Zitat Titova N, Chaudhuri KR (2017) Personalized medicine in Parkinson’s disease: time to be precise. Int Rev Neurobiol 134:33–54CrossRef Titova N, Chaudhuri KR (2017) Personalized medicine in Parkinson’s disease: time to be precise. Int Rev Neurobiol 134:33–54CrossRef
Zurück zum Zitat Titova N, Qamar MA, Chaudhuri KR (2017) Biomarkers of Parkinson’s disease: an introduction. Int Rev Neurobiol 132:183–196CrossRef Titova N, Qamar MA, Chaudhuri KR (2017) Biomarkers of Parkinson’s disease: an introduction. Int Rev Neurobiol 132:183–196CrossRef
Zurück zum Zitat van den Eaden S, Tanner C, Bernstein A et al (2003) Incidence of Parkinson’s disease: variations by age, gender and race/ethnicity. Am J Epidemiol 157:1015–1022CrossRef van den Eaden S, Tanner C, Bernstein A et al (2003) Incidence of Parkinson’s disease: variations by age, gender and race/ethnicity. Am J Epidemiol 157:1015–1022CrossRef
Zurück zum Zitat van Rooden SM, Colas F, Martínez-Martín P, Visser M, Verbaan D, Marinus J, Chaudhuri RK, Kok JN, van Hilten JJ (2011) Clinical subtypes of Parkinson’s disease. Mov Disord 26(1):51–58CrossRef van Rooden SM, Colas F, Martínez-Martín P, Visser M, Verbaan D, Marinus J, Chaudhuri RK, Kok JN, van Hilten JJ (2011) Clinical subtypes of Parkinson’s disease. Mov Disord 26(1):51–58CrossRef
Zurück zum Zitat Wickremaratchi MM, Knipe MD, Sastry BS, Morgan E, Jones A, Salmon R, Weiser R, Moran M, Davies D, Ebenezer L, Raha S, Robertson NP, Butler CC, Ben-Shlomo Y, Morris HR (2011) The motor phenotype of Parkinson’s disease in relation to age at onset. Mov Disord 26:457–463CrossRef Wickremaratchi MM, Knipe MD, Sastry BS, Morgan E, Jones A, Salmon R, Weiser R, Moran M, Davies D, Ebenezer L, Raha S, Robertson NP, Butler CC, Ben-Shlomo Y, Morris HR (2011) The motor phenotype of Parkinson’s disease in relation to age at onset. Mov Disord 26:457–463CrossRef
Metadaten
Titel
Creation of a gene expression classifier for predicting Parkinson’s disease rate of progression
verfasst von
Jose Martin Rabey
Jennifer Yarden
Nir Dotan
Danit Mechlovich
Peter Riederer
Moussa B. H. Youdim
Publikationsdatum
08.05.2020
Verlag
Springer Vienna
Erschienen in
Journal of Neural Transmission / Ausgabe 5/2020
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-020-02194-y

Weitere Artikel der Ausgabe 5/2020

Journal of Neural Transmission 5/2020 Zur Ausgabe

Neurology and Preclinical Neurological Studies - Review Article

Selegiline: a molecule with innovative potential

Neurology and Preclinical Neurological Studies - Review Article

Non-pharmacological management of cognitive impairment in Parkinson’s disease

Neurology and Preclinical Neurological Studies - Review Article

Treatment of tics associated with Tourette syndrome

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.